GlassScriptPhysician profile
Chelsie E Seffens
NPI 1548809098
$614.59
in general payments reported to CMS, 2019-2025
15 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $103 · 2022: $83.63 · 2023: $116 · 2024: $197 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $427.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $90.65 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $87.48 | 2021-2025 | |
| Novo Nordisk INC | $58.91 | 2022-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $48.18 | 2023-2025 | |
| Amgen INC. | $44.98 | 2021-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $42.15 | 2021 | |
| Xeris Pharmaceuticals, INC. | $39.52 | 2023-2024 | Gvoke Hypopen |
| Lilly USA, LLC | $34.13 | 2021-2024 | Mounjaro |
| Exact Sciences Corporation | $32.49 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.02 | 2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $30.54 | 2022-2025 | Capvaxive, Rotateq, Gardasil 9 |
| Pfizer INC. | $29.25 | 2024 | |
| Sanofi Pasteur INC. | $19.43 | 2023 | |
| Sanofi-Aventis U.S. LLC | $12.49 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chelsie Seffens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.